Medtronic MiniMed 780G Data Shows Simplified Meal Management Helps Users With Glycemic Target

Medtronic announced data at the ADA conference today showing the MiniMed 780G advanced hybrid close loop system’s meal detection technology helps reduce time spent in hyperglycemia.

American Diabetes Association Annual Meeting 2023: San Diego, California, USA - January 29, 2018: A panoramic morning view of San Diego Marina, surrounded by modern high-rising buildings, at side of San Diego Bay in Marina District of the Downtown.
• Source: Shutterstock

New trial results showed Medtronic plc’s MiniMed 780G insulin pump system can help users maintain glycemic targets while providing forgiveness for inexact carb counts.

The study evaluated the system across a wide range of users, including younger patients who are known to often have...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Diabetic Care

Dexcom Builds Momentum Ahead of 15-Day G7 Launch, Eyes AI and G8 for Growth

 
• By 

Dexcom introduced a new AI-powered smart food logging feature in its Stelo and G7 platforms. This tool allows users to generate detailed meal descriptions from photos and analyzes the glycemic impact of those meals.

Injuries And Deaths Linked To Baxter Infusion Pump

 

The US FDA says Baxter has notified customers about an issue with its Novum IQ Syringe Pump that is linked to two deaths and multiple injuries.

Medtronic’s MiniMed Expands EU Uses Of MiniMed 780G And Readies For US Expansion Amid Competition

 
• By 

The timing aligns with Medtronic’s plan to spin off its $2.8bn diabetes unit, now named MiniMed. As a standalone entity, MiniMed will be more responsive to competition, regulatory shifts, and the diabetes technology needs of healthcare systems.

Abbott Lowers Outlook But Headwinds Are Temporary

 

Despite headwinds, executives remain optimistic about growth in Abbott’s medical devices and diabetes divisions and plan several product rollouts, including the Volt PFA catheter for electrophysiology and the dual glucose-ketone sensor CGM.

More from Device Area

FDA Panel Supports Dermal Fillers For Décolletage Use

 
• By 

An FDA panel has endorsed the use of dermal fillers for décolletage, but warned of patient safety concerns. The filler can cause complications with future imaging and pregnancy or breastfeeding, panelists said. Regulatory measures and patient studies are recommended for better outcomes.

After Thought-Control Demo, Synchron Plans Pilot Study With Upgraded BCI On Path To Pivotal Trial

 
• By 

Synchron is preparing a pilot study of its fully wireless, second-gen brain-computer interface after an ALS patient controlled an iPad solely by thought. If all goes as planned, Synchron’s BCI will move into pivotal trials in 2026.

Apreo Health Raises $130M, First Patient Treated In US Clinical Trial

 

Apreo Health CEO Karun Naga talks to Medtech Insight about the company’s intentions for its Series B funding. The Breathe-3 clinical trial and early commercialization activities, involving physician education, are top priorities.